Norpace CR — Class III drug recall D-0520-2016
Terminated recall by Pfizer Inc., reported 2015-12-16, distributed nationwide. Failed Dissolution Specification
| Recall number | D-0520-2016 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2015-12-02 |
| Classified | 2015-12-10 |
| Reported by FDA | 2015-12-16 |
| Terminated | 2017-07-26 |
| Distributed | Nationwide (US) |
| Reason classes | specification failure |
| NDC | 00025-2732, 00025-2732-31, 00025-2742, 00025-2742-31, 00025-2742-51, 00025-2752, 00025-2752-31, 00025-2762, 00025-2762-31 |
| Lot numbers | 6/16, C150064, C150065 |
Product
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.
Reason for recall
Failed Dissolution Specification
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0520-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.